IN2014MN01594A - - Google Patents

Info

Publication number
IN2014MN01594A
IN2014MN01594A IN1594MUN2014A IN2014MN01594A IN 2014MN01594 A IN2014MN01594 A IN 2014MN01594A IN 1594MUN2014 A IN1594MUN2014 A IN 1594MUN2014A IN 2014MN01594 A IN2014MN01594 A IN 2014MN01594A
Authority
IN
India
Prior art keywords
agent
strain
mtb
allergic
asthma
Prior art date
Application number
Other languages
English (en)
Inventor
Iglesias Pere Joan Cardona
Riera Isabel Amat
Moreno Blanca Reyes
Fabregat Maria Mercè Amat
Original Assignee
Archivel Farma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archivel Farma Sl filed Critical Archivel Farma Sl
Publication of IN2014MN01594A publication Critical patent/IN2014MN01594A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/001Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN1594MUN2014 2012-01-12 2012-01-12 IN2014MN01594A (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2012/000353 WO2013104943A1 (en) 2012-01-12 2012-01-12 Mtb-c vaccine against asthma

Publications (1)

Publication Number Publication Date
IN2014MN01594A true IN2014MN01594A (enExample) 2015-05-08

Family

ID=45852617

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1594MUN2014 IN2014MN01594A (enExample) 2012-01-12 2012-01-12

Country Status (15)

Country Link
US (1) US9682042B2 (enExample)
EP (1) EP2802345B1 (enExample)
CN (1) CN104411326B (enExample)
AU (1) AU2012365465B2 (enExample)
BR (1) BR112014017217B1 (enExample)
CA (1) CA2861074C (enExample)
DK (1) DK2802345T3 (enExample)
ES (1) ES2670493T3 (enExample)
IN (1) IN2014MN01594A (enExample)
NO (1) NO2802345T3 (enExample)
PL (1) PL2802345T3 (enExample)
PT (1) PT2802345T (enExample)
RU (1) RU2602771C2 (enExample)
WO (1) WO2013104943A1 (enExample)
ZA (1) ZA201405107B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103720657B (zh) * 2013-11-19 2017-01-04 广东丸美生物技术股份有限公司 一种可变形脂质体的制备方法,及其制备的可变性脂质体
RU2652752C1 (ru) * 2017-06-15 2018-04-28 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фундаментальной и клинической иммунологии" Способ лечения бронхиальной астмы
EP3797791A1 (en) * 2019-09-26 2021-03-31 Universidad De Zaragoza Therapeutic efficacy by pulmonary delivery of live attenuated mycobacteria

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0811075B1 (en) 1995-02-22 2008-05-14 Adcock Ingram Limited A method for the isolation and purification of lipid cell-wall components
GB9813100D0 (en) 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
BR0103887C1 (pt) 2001-07-17 2005-11-08 Univ Minas Gerais Composições imunogênicas contendo microesferas biodegradáveis encapsulando antìgenos, vetores gênicos e adjuvantes
ES2231037B1 (es) * 2003-10-31 2005-12-16 Archivel Technologies, Sl Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
JP2008505106A (ja) 2004-07-01 2008-02-21 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア ハイスループットプロテオミクス
ES2381492T3 (es) 2005-04-29 2012-05-28 Glaxosmithkline Biologicals Sa Procedimiento de prevención o tratamiento de infección por M. tuberculosis
WO2007022152A2 (en) 2005-08-15 2007-02-22 The Research Foundation Of State University Of New York Lipid nano particulates containing antigens as cancer vaccines
EP1954252B1 (en) 2005-12-02 2016-02-03 GlaxoSmithKline Biologicals SA Nanoparticles for use in immunogenic compositions
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
CA2649528A1 (en) 2006-04-20 2007-11-01 Tokai University Educational System Therapeutic agent for allergy containing liposome having oligosaccharide on its surface
EP2076244B1 (en) 2006-10-10 2016-12-07 Jina Pharmaceuticals Inc. Aqueous systems for the preparation of lipid-based pharmaceutical compounds; compositions, methods, and uses thereof
ES2307402B1 (es) 2006-10-30 2009-09-30 Archivel Farma, S.L. Vacuna profilactica contra la tuberculosis.
WO2009089535A2 (en) 2008-01-11 2009-07-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polypeptide vaccine and vaccination strategy against mycobacterium
ES2335177B1 (es) * 2008-09-19 2011-02-28 Archivel Farma, S.L. Agente inmunoterapeutico apropiado para la profilaxis primaria de la tuberculosis.
US9074001B2 (en) 2009-04-24 2015-07-07 Statens Serum Institut Tuberculosis TB vaccine to prevent reactivation
SG190731A1 (en) 2010-12-14 2013-07-31 Glaxosmithkline Biolog Sa Mycobacterium antigenic composition

Also Published As

Publication number Publication date
BR112014017217A2 (pt) 2017-06-13
CN104411326B (zh) 2018-02-02
ZA201405107B (en) 2020-11-25
RU2014133042A (ru) 2016-02-27
DK2802345T3 (en) 2018-04-30
RU2602771C2 (ru) 2016-11-20
US9682042B2 (en) 2017-06-20
US20150132364A1 (en) 2015-05-14
PL2802345T3 (pl) 2018-08-31
EP2802345A1 (en) 2014-11-19
PT2802345T (pt) 2018-04-24
NO2802345T3 (enExample) 2018-08-04
WO2013104943A1 (en) 2013-07-18
EP2802345B1 (en) 2018-03-07
AU2012365465A1 (en) 2014-08-21
BR112014017217A8 (pt) 2017-07-04
BR112014017217B1 (pt) 2023-01-17
CN104411326A (zh) 2015-03-11
ES2670493T3 (es) 2018-05-30
AU2012365465B2 (en) 2017-05-18
CA2861074A1 (en) 2013-07-18
CA2861074C (en) 2018-11-06

Similar Documents

Publication Publication Date Title
EA201390049A1 (ru) Сухой порошковый препарат, содержащий ингибитор фосфодиэстеразы
WO2014045254A3 (en) Human betacoronavirus lineage c and identification of n-terminal dipeptidyl peptidase as its virus receptor
HK1212249A1 (en) Bioconjugates comprising modified antigens and uses thereof
MX2013003817A (es) Supresion de una respuesta inmunologica de hipersensibilidad con antigeno no relacionado derivado de material de fuente de alergeno.
MX2022004103A (es) Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad.
WO2014127917A8 (en) Combination of vaccination and inhibition of the pd-1 pathway
IN2015KN00414A (enExample)
HK1219022A1 (zh) 填充胃肠道的方法
EA201291306A1 (ru) Состав сухого порошка, содержащий антимускариновое средство
MX2016010373A (es) Rapamicina para el tratamiento de linfangioleiomiomatosis.
WO2013098655A3 (en) Vaccines directed against human enteroviruses
MX381173B (es) Rapamicina para el tratamiento de linfangioleiomiomatosis.
WO2013059559A3 (en) Compounds and methods for enhancing innate immune responses
MX2016009306A (es) Reequilibrado inmunologico epicutaneo.
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
WO2012071369A3 (en) A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
MX364800B (es) Tilmicosina de accion prolongada mejorada y el uso de la misma en el tratamiento del complejo respiratorio bovino (crb) y en el periodo de la vaca seca.
WO2014205199A3 (en) Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
MX2015006370A (es) Suplementos herbales y metodos para utilizar los mismos.
WO2014052780A3 (en) Compositions and methods of use of an inappetance-controlling compound
SG10201807682PA (en) Methods of Treating or Preventing Respiratory Conditions
IN2014MN01594A (enExample)
SG10201908089VA (en) Novel dosing regimens of celgosivir for the treatment of dengue
WO2016122289A3 (ko) 베르베논 유도체를 포함하는 재관류 시술의 부작용을 감소 또는 예방하기 위한 조성물
WO2014074817A3 (en) Attenuated mannheimia haemolytica vaccines and methods of making and use